



THE CHALLENGE OF CHILDHOOD CANCER

¹Mrs. Aishwarya P. Pimple, ²Mr. Akash B. Ghuge, ³Dr. Gajanan Sanap.

⁴Mr. Avinash D. Manke, ⁵Mr. Jayraj S. Mhaske.

¹Assistant Professor, ²Student, ³Principal, ⁴Student, ⁵Student

¹Quality Assurance

¹Late Bhagirathi Yashwantrao Pathrikar College of Pharmacy (D & B. Pharmacy) Pathri, Aurangabad, Maharashtra, India.

Abstract: Advances with inside the remedy of childhood cancers have led to component from the improvement of national and global collaborative tasks which have described biologic determinants and generated risk-adapted healing procedures that maximize therapy whilst minimizing acute and long-time period effects. Currently, greater than 80% of children with cancer who're treated with modern multidisciplinary remedies in advanced international locations are cured; however, of the about 160,000 children and youth who're identified with cancer each yr. worldwide, 80% stay in low- and middle-earnings international locations (LMICs), wherein get admission to best care is confined and probabilities of therapy are low. In addition, the disease burden isn't always absolutely regarded due to the shortage of population-based cancer registries in low-useful resource international locations. Regional and ethnic versions within side the occurrence of the different childhood cancers recommend precise interactions among genetic and environmental elements that would offer possibilities for etiologic studies. Regional collaborative tasks were advanced in Central and South America and the Caribbean, Africa, the Middle East, Asia, and Oceania. These tasks combine nearby capability building, training of fitness care providers, implementation of intensity-graduated remedies, and established order of studies applications which might be adjusted to nearby capability and nearby needs.

Key Point: Childhood cancer, Remedy, illnesses.

Introduction:

Children with cancer who stay in high-earnings nations (HICs) have correct results, with about 80% surviving five years after their diagnosis.^[1,2] However, more than 90% of children vulnerable to growing childhood cancer every yr. stay in low-earnings and middle-earnings nations (LMICs).^[3,4] Considered through many as one of the essential advances of modern science, the development in results in kids with cancer visible in HICs during the last numerous many years has now no longer translated to maximum LMICs, in which present records recommend that a long way fewer children survive.^[5] An correct appraisal of childhood cancer incidence and results is non-existent in lots of LMICs, due in component to a loss of the cancer registry and important registration structures essential to file and file those records.^[4,6] Childhood cancers are frequently deadly without suitable and well-timed diagnosis and remedy and, by comparison with adult cancers, there are no evidence-based population screening programmes or life-style risk-reduction techniques which are powerful in enhancing results.^[7,8] As a result, growing survival would require considerable making plans through coverage makers to make sure adequate useful resource allocation and fitness system function. Information at the burden of childhood cancer is important to informing those efforts and thus, model-primarily based totally estimates are important to decide cancer burden in settings without records till cancer records insurance improves. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 gives estimates for 359 illnesses and injuries, including cancers, and is therefore uniquely placed to fill the distance in fitness making plans records as nations work to extend their cancer surveillance systems.^[9] Additionally, preferred GBD results consist of estimates of disability-adjusted life-years (DALYs), a beneficial composite metric that bills for each the mortality and morbidity of a disorder.^[10] DALYs permit for cross-disease and cross-geography comparisons that contextualise disease burden. So a long way, however, no dedicated GBD evaluation of childhood cancer burden has been done. Previous studies describing childhood cancer burden across the world has targeted on traditional metrics of cancer burden, together with incidence, mortality, and survival.^[5, 6, 11]

Patterns of Childhood Cancer Survival:

Over the beyond many years, advances in molecular biology, imaging, and chemotherapy with remedy stratification directed by the somatic mutations and early reaction to chemotherapy, higher use of conventional anticancer agents, and advanced supportive care, have caused considerable upgrades in treatment charges of childhood cancers^[48, 49-50]. In HICs, the five-yr. survival of childhood cancer overall has progressed from 30% with inside the 1960s to greater than 80% nowadays^[48, 51, 52]. However, now no longer all children gain from those upgrades and significant variations in survival charges are visible among nations. These inequalities are located inside each high-useful resource areas which include Europe, with ~10% poorer survival in Eastern European nations in comparison to the rest of Europe^[48], and to a far large extent in LMICs^[52, 53]. Similarly, to the occurrence of childhood cancer, dependable records on childhood cancer survival in LMICs is scarce, however shows extensively decrease survival charges^[54, 55, 56] than the ones observed in HICs^[48, 51, 52]. Those diagnoses account for about 4% of cancers diagnosed in children aged 0 to 14 years, compared with about 20% of cancers diagnosed in adolescents aged 15 to 19 years refer to “**Fig. 1**” and “**Fig.2**”.^[57]




figure 1: age-adjusted and age-specific (0–14 years) surveillance, epidemiology, and end results (seer) cancer incidence rates from 2009 to 2012 by international classification of childhood cancer group and subgroup and age at diagnosis, including myelodysplastic syndrome and group iii benign brain/central nervous system tumours for all races, males, and females.

Age-Adjusted and Age-Specific Cancer Incidence Rates for Patients Aged 15–19 Years (SEER 2009–2012)

- Epithelial
- CNS
- Lymphoma
- Leukemia
- Germ cell
- Soft tissue
- Bone
- Renal
- Liver
- Neuroblastoma
- Other




figure 2 : age-adjusted and age-specific (15–19 years) surveillance, epidemiology, and end results (seer) cancer incidence rates from 2009 to 2012 by international classification of childhood cancer group and subgroup and age at diagnosis, including myelodysplastic syndrome and group iii benign brain/central nervous system tumours for all races, males, and females.

Expectations of Family Caregivers/Parental Caregiving Dilemma and Role Conflict:

Because cancer is so uncommon and sudden in childhood, there's no guidance for the role of the parent (or grandparent or sibling) of a child with cancer. During the preliminary diagnosis duration, the family, mainly the mother and father, should adjust to this identification and role shift. Sometimes this identification transition starts earlier than diagnosis (mother and father may also have suspected that their child became now no longer nicely and might have brought her/him to more than one medical doctors earlier than actually receiving the oncology diagnosis). In addition to the parental nurturing provided while a child is nicely, mother and father of children with cancer frequently find out that they should become advocates, counsellors, and clinical technicians on this new role. Expectations of family caregivers of children with cancer are pretty high. The oncology group expects mother and father to quick study and cling to rigorous remedy protocols that frequently contain common clinical appointments and/or prolonged health facility stays. Parents commonly deliver home-primarily based totally high-tech hospital treatment this is frequently complicated and invasive. Parents emerge as educated to discover and reply to severe and distressing side effects of remedies which could consist of nausea, vomiting, pain, sleeplessness, and changes in attitude, mood, behaviour, consuming and sleeping patterns, fever and neutropenia, distress, and struggling. Parents are sometimes requested to assist the clinical team with the aid of using getting their child to conform and cooperate with invasive procedures. The parental caregiver dilemma includes mother and father having to offer care this is frequently painful and scary to the kid whilst simultaneously desiring to explain, hold, nurture, comfort, protect, and assist their child keep away from suffering and pain. Families of children with cancer may also offer clinical, emotional, financial, spiritual, or physical caregiving, or much more likely a mixture of all of those. ^[45]Medical caregiving includes the control of remedy, clinic stays, health centre visits, home care, and any range of different remedy-associated tasks. The context of this caregiving may be pretty emotionally taxing, as defined by this mother. "Every 4 or 5 days, we needed to sterilize the location in which the catheter went into Forrest's body. The hollow for the catheter became proper beside his heart. Infection there could kill him quick. We had been shown a way to easy the catheter site with inside the first few days of his diagnosis. One of our nurses confirmed the usage of a plastic infant doll. But the doll failed to squirm. The doll failed to feel any pain. As I watched her, I knew our experience was going to be an entire different story..."^[46] Parents file that the maximum common bad impact from parental caregiving is on their physical and emotional fitness.^[47] Parents suggest that the varieties of assistance which are maximum useful to them consist of respite from direct caregiving and comfort from different duties so they'll awareness on the kid.^[47] According to mother and father in a single survey, the maximum

beneficial kinds of help to relieve caregiver burden include well timed training approximately their child's fitness status from fitness care providers and emotional help from family members, friends, and others.^[47]

Mother's illnesses and tablets taken in being pregnant:

The records display considerable excesses of reported illnesses and tablets administered a few of the cases in comparison with the controls,^[26] however deciphering those is mainly tough due to the possibility of take into account bias and additionally the trouble of distinguishing the results of the infection and the remedy. Thus Sanders, Draper^[27] tested the superiority of pulmonary tuberculosis and epilepsy, each significantly extra common in case moms than in controls. They demonstrated, however, that the proportions of moms affected by infection that had been prescribed sure tablets, particularly ionized and phenytoin had been comparable among instances and controls, suggesting that association can be attributed to the disease instead of the remedy. In an extra complete examine, Gilman et al.^[28] provided an evaluation of all recorded tablets and illnesses the usage of logistic regression, which correctly adjusted estimates of individual drug or infection results for normal case-manage reporting variations. They concluded that the results of medicine taken in the course of being pregnant had been secondary to the ones of sure illnesses, significantly viral infections and different illnesses related to pyrexia. The simplest drug agencies with steady residual outcomes with inside the evaluation had been analgesics, antipyretics and vaccines.

Parental tobacco and alcohol consumption:

A study of 1641 matched pairs for the times 1977 – 81^[29] revealed no important effect of maternal alcohol consumption or motherly smoking on nonage cancer threat, but a largely significant trend with tobacco use by the children's fathers ($P < 0.001$), attesting an association plant from other, lower studies. This trend was also verified in analyses of data from the OSCC for two another ages, the effect applying across tumour groups, though concentrated substantially on leukaemia's and tubercles. Sorahan et al.^[30] Present the data for 1953 – 55 and review the literature, while Sorahan et al.^[31]

Childhood cancer in twins:

Twins are much less possibly than singletons to increase childhood malignant disease. Hewitt et al.^[33] recommended that this become due to the fact a member of a pair affected in utero can also additionally have an multiplied danger of death earlier than the twin being pregnant is recognized as such. They argued that this end become supported through the locating that the twin deficit implemented mainly to members of like-intercourse pairs, and that this will reflect prenatal choice in opposition to embryos with a disposition to increase cancer in childhood. Twin concordance, the probability of each members of a twin pair having childhood cancer, is mentioned in Draper et al.;^[32] that discussion is primarily based totally partially on findings from the OSCC.

Surveillance of cancer in children:

Within the overall cancer surveillance framework that calls on information on danger factors, incidence, survival, and mortality^[34], the surveillance of childhood most cancers has particular factors to consider, as highlighted next. Given the present day information of preventable danger factors for childhood cancer, there are limited grounds for the populace-primarily based totally surveillance of danger factors and precancerous situations in children. Rather, emphasis is placed at the provision of fantastic facts on incidence, survival, overdue effects, and excellent of lifestyles of survivors. Cancer manage in children is knowledgeable through detailed facts at the disease, treatment, and first-rate of care, and thus, the gathering of facts on diagnosis, treatment, and long-time period follow-up of a developing populace of survivors has emerge as an necessary a part of childhood cancer surveillance.^[35, 36] Childhood cancers represent a small percentage of cancers, about 1%-2% of all cancers^[38, 39], with the percentage various consistent with the age distribution of the populace. In nations with low Human Development Index, wherein populations are younger, children constitute a bigger percentage of cancer sufferers as compared with nations with very excessive Human Development Index and older populations (0.4% vs. 5%, respectively) "**Fig 3**". Furthermore, morphological types of cancers occurring in childhood vary considerably in comparison with those among adults^[37].




Figure 3: Distribution of the estimated numbers of new cancer cases by age group in settings categorized by human.

Chemotherapy and SMN Development:

The best-set up affiliation among chemotherapy and SMNs is for therapy-associated acute myeloid leukemia (t-AML) and therapy-associated myelodysplastic syndrome (t-MDS). Dose-based dangers for t-AML and t-MDS are high (> 10-fold increased) after nearly all alkylating agents, in addition to topoisomerase II inhibitors^[12, 13]; however, the leukemogenicity of various agents varies drastically and the AER is low due to the low heritage chance. T-AML after alkylating-agent publicity usually arises after a latency of five to eight years, is regularly preceded by MDS, and regularly has a complicated karyotype with chromosome five and seven abnormalities. In contrast, t-AML after topoisomerase II inhibitor exposure usually arises < 3> 10 years after exposure.

Genetics and SMN Development:

Genomic advances with inside the closing decade have elevated our knowledge of cancer predisposition. Broadly, genetic contributions to most cancers variety from rare, exceedingly penetrant variations which are regularly related to familial cancer susceptibility syndromes to greater common genetic variations related to weakly or modestly increased chance for cancer with inside the general population. Multiple primary cancers inside an character can arise in numerous cancer susceptibility syndromes^[17]; In the overall population, maximum research have focused on genetic variant in DNA harm detection and restore mechanisms as capacity modifiers of remedy-associated SMN dangers, as reviewed recently.^[16] However, those researches are limited by small sample sizes, inadequate remedy publicity data, or loss of replication of the reported findings. More recently, research have agnostically interrogated not unusual place genetic variant throughout the genome to discover variations related to SMN chance, along with research of t-MDS and t-AML,^[17] SMNs after HL, and breast cancer after childhood cancer. Expansion of that research via large-scale genomics efforts in survivors of cancer, which include the CCSS and the SJLIFE Cohort, ought to offer critical insights into the position of genetic susceptibility in more than one primary cancer.^[18]

Long-time period consideration:

Caedite eos! Novit enim Dominus qui sunt eius already suggests that destroying a populace isn't possible without collateral harm. In adult cancer, we see this predominantly with inside the short-time period complications of remedy, together with fatigue, diarrhea, nausea, and vomiting and hair loss, in addition to neuropathy, anaemia and thrombocytopenia. In paediatric oncology, one additionally has to don't forget the long-time period implications, as successful remedy hopefully way the affected person has

every other 3 rating and 10 years to live. In a current evaluate discussing radiation and mind tumours we identify the subsequent complications, which would possibly rise up from the use of cell death-inducing remedy in children: A link has been postulated among the publicity of children to radiotherapy for leukemia and the general danger of growing glioblastoma.^[19] Childhood most cancers survivors have elevated dangers for numerous malignancies later in lifestyles together with Acute Myeloid Leukaemia (AML), Non-Hodgkin lymphoma and colorectal cancer.^[20,21] Already in 1969, Bloom and co-employees proven cognitive dementia amongst survivors of childhood medulloblastoma^[22], and at the same time as a few in advance research recommended that the tumour is probably the causative agent for discount in IQ, maximum large-scale research agree that radiotherapy is an impartial danger factor. Importantly, more youthful age of affected person at remedy, radiation dose and time since remedy enhance the neurological deficits^[23]. This would possibly recommend that radiotherapy damages the pool of neurological stem cells, replenishment turning into increasingly more inefficient with growing age, and as a consequence neurological deficits growing. This speculation is supported by the observation that conformal avoidance of the hippocampal neural stem cell compartment reduces neurological aspect effect^[24]. While radiation, by the character of localized application, has alternatively particular aspect effects, regularly referring to the tumour-harboring organs, chemotherapy is given systemically and consequently an extensive variety of aspect effects is to be expected. Indeed, right here we discover growth, intellectual improvement and access into puberty being delayed, in addition to decreased fertility and organ-particular harm, especially to heart and lungs. Importantly, the unique harm caused by toxicity is regularly unrecognized or subclinical on the time and most effective at some stage in improvement, while the tissue is uncovered to further stress, do the long-time period aspect effects become apparent^[25].

Future Directions:

Despite the exceptional advances which have led to children with cancer having an approximate 80% universal chance of 5-yr event-unfastened survival, childhood cancer stays the main reason of dying from disorder in children with inside the United States, and treatment-associated morbidity and mortality stay substantial issues each at some stage in remedy and nicely into survivorship. Targeted new agents keep the chance for extra effective and much less poisonous treatment; however, to date, most effective restricted numbers of children with cancer, which include children with anaplastic big cell lymphomas^[40] and subsets of children with ALL, seem probably to derive significant long-time period enjoy the current generation of targeted new agents, with lively research ongoing for children with AML, neuroblastoma, Ewing sarcoma, medulloblastoma, and different subsets of cancer. The interesting possibilities for cellular remedy and immunotherapy, that have been highlighted with new agents which include blinatumomab^[41,42] and chimeric antigen receptor-changed T cells^[43,44] for children with CD19-expressing B-lineage lymphoblastic leukemia, are poised to feature incredibly effective new healing modalities to the paediatric oncology portfolio. The collaborative studies infrastructure for children with cancer is nicely located to maintain to improve novel remedies into medical investigations for a spectrum of uncommon and ultrarare childhood cancers. As our information of the molecular basis of childhood cancers maintains to increase, there could be extra want for international collaboration in paediatric scientific-translational oncologic studies, due to the fact the already small populations of children diagnosed with precise cancers could be similarly divided into smaller subpopulations. More powerful alignment among the biopharmaceutical industry, international regulatory agencies, educational investigators, and different stakeholders (which include, of course, affected person families) is needed. Legislative efforts have made a modest effect on childhood cancer drug improvement, however big refinement in numerous regions is wished. An extra funding of assets in goal discovery and validation can assist drive lots needed improvement of new, extra powerful remedies for children with cancer and afford them now no longer most effective healing procedures however healing procedures freed from the too frequently lifelong burden of current-day cancer remedies.

Conclusion:

Regarding the extended trend of childhood cancer incidence, there may be an important want to deal with the etiologic elements and set up preventive plans for childhood cancers. Despite the favourable consequences determined in cancer care, commensurate fitness useful resource allocation should be implemented to decrease the subnational disparities.

REFERENCES:

- [1]. Noone, A.M., Howlader, N., Krapcho, M., Miller, D., Brest, A., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., Lewis, D.R. and Chen, H.S., 2018. SEER Cancer Statistics Review, 1975–2015. Bethesda, MD: National Cancer Institute; April 2018.
- [2]. Gatta, G., Botta, L., Rossi, S., Aareleid, T., Bielska-Lasota, M., Clavel, J., Dimitrova, N., Jakab, Z., Kaatsch, P., Lacour, B. and Mallone, S., 2014. Childhood cancer survival in Europe 1999–2007: results of EURO-CARE-5—a population-based study. *The lancet oncology*, 15(1), pp.35–47.
- [3]. Rodriguez-Galindo, C., Friedrich, P., Alcasabas, P., Antillon, F., Banavali, S., Castillo, L., Israels, T., Jeha, S., Harif, M., Sullivan, M.J. and Quah, T.C., 2015. Toward the cure of all children with cancer through collaborative efforts: pediatric oncology as a global challenge. *Journal of Clinical Oncology*, 33(27), p.3065.
- [4]. Bhakta, N., Force, L.M., Allemani, C., Atun, R., Bray, F., Coleman, M.P., Steliarova-Foucher, E., Frazier, A.L., Robison, L.L., Rodriguez-Galindo, C. and Fitzmaurice, C., 2019. Childhood cancer burden: a review of global estimates. *The lancet oncology*, 20(1), pp.e42–e53.
- [5]. Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., Bonaventure, A., Valkov, M., Johnson, C.J., Estève, J. and Ogunbiyi, O.J., 2018. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. *The Lancet*, 391(10125), pp.1023–1075.

- [6]. Steliarova-Foucher, E., Colombet, M., Ries, L.A., Moreno, F., Dolya, A., Bray, F., Hesselting, P., Shin, H.Y., Stiller, C.A., Bouzbid, S. and Hamdi-Cherif, M., 2017. International incidence of childhood cancer, 2001–10: a population-based registry study. *The Lancet Oncology*, 18(6), pp.719-731.
- [7]. Gupta, S., Howard, S.C., Hunger, S.P., Antillon, F.G., Metzger, M.L., Israels, T., Harif, M. and Rodriguez-Galindo, C., 2015. Treating childhood cancer in low-and middle-income countries. *Cancer*. Washington DC: The World Bank Group, pp.121-46.
- [8]. Sankaranarayanan, R., 2014. Screening for cancer in low-and middle-income countries. *Annals of global health*, 80(5), pp.412-417.
- [9]. Fitzmaurice, C., Akinyemiju, T.F., Al Lami, F.H., Alam, T., Alizadeh-Navaei, R., Allen, C., Alsharif, U., Alvis-Guzman, N., Amini, E., Anderson, B.O. and Aremu, O., 2018. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. *JAMA oncology*, 4(11), pp.1553-1568.
- [10]. Murray, C.J., 1994. Quantifying the burden of disease: the technical basis for disability-adjusted life years. *Bulletin of the World health Organization*, 72(3), p.429.
- [11]. Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D.M., Piñeros, M., Znaor, A. and Bray, F., 2019. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. *International journal of cancer*, 144(8), pp.1941-1953.
- [12]. Travis, L.B., Wahnefried, W.D., Allan, J.M., Wood, M.E. and Ng, A.K., 2013. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. *Nature reviews Clinical oncology*, 10(5), pp.289-301.
- [13]. Pui, C.H., Ribeiro, R.C., Hancock, M.L., Rivera, G.K., Evans, W.E., Raimondi, S.C., Head, D.R., Behm, F.G., Mahmoud, M.H., Sandlund, J.T. and Crist, W.M., 1991. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. *New England Journal of Medicine*, 325(24), pp.1682-1687.
- [14]. Pendleton, M., Lindsey Jr, R.H., Felix, C.A., Grimwade, D. and Osheroff, N., 2014. Topoisomerase II and leukemia. *Annals of the New York Academy of Sciences*, 1310(1), p.98.
- [15]. Lindor, N.M., McMaster, M.L., Lindor, C.J. and Greene, M.H., 2008. Concise handbook of familial cancer susceptibility syndromes. *JNCI monographs*, 2008(38), pp.3-93.
- [16]. Bhatia, S., 2015. Genetic variation as a modifier of association between therapeutic exposure and subsequent malignant neoplasms in cancer survivors. *Cancer*, 121(5), pp.648-663.
- [17]. Knight, J.A., Skol, A.D., Shinde, A., Hastings, D., Walgren, R.A., Shao, J., Tennant, T.R., Banerjee, M., Allan, J.M., Le Beau, M.M. and Larson, R.A., 2009. Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. *Blood, The Journal of the American Society of Hematology*, 113(22), pp.5575-5582.
- [18]. Best, T., Li, D., Skol, A.D., Kirchhoff, T., Jackson, S.A., Yasui, Y., Bhatia, S., Strong, L.C., Domchek, S.M., Nathanson, K.L. and Olopade, O.I., 2011. Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma. *Nature medicine*, 17(8), pp.941-943.
- [19]. Neglia, J.P., Robison, L.L., Stovall, M., Liu, Y., Packer, R.J., Hammond, S., Yasui, Y., Kasper, C.E., Mertens, A.C., Donaldson, S.S. and Meadows, A.T., 2006. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. *Journal of the National Cancer Institute*, 98(21), pp.1528-1537.
- [20]. Rihani, R., Bazzeh, F., Faqih, N. and Sultan, I., 2010. Secondary hematopoietic malignancies in survivors of childhood cancer: An analysis of 111 cases from the Surveillance, Epidemiology, and End Result-9 registry. *Cancer*, 116(18), pp.4385-4394.
- [21]. Henderson, T.O., Oeffinger, K.C., Whitton, J., Leisenring, W., Neglia, J., Meadows, A., Crotty, C., Rubin, D.T., Diller, L., Inskip, P. and Smith, S.A., 2012. Secondary gastrointestinal cancer in childhood cancer survivors: a cohort study. *Annals of internal medicine*, 156(11), pp.757-766.
- [22]. Bloom, H.J.G., Wallace, E.N.K. and Henk, J.M., 1969. The treatment and prognosis of medulloblastoma in children: a study of 82 verified cases. *American Journal of Roentgenology*, 105(1), pp.43-62.
- [23]. Palmer, S.L., 2008. Neurodevelopmental impact on children treated for medulloblastoma: a review and proposed conceptual model. *Developmental disabilities research reviews*, 14(3), pp.203-210.
- [24]. Gondi, V., Pugh, S.L., Tome, W.A., Caine, C., Corn, B., Kanner, A., Rowley, H., Kundapur, V., DeNittis, A., Greenspoon, J.N. and Konski, A.A., 2014. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. *Journal of Clinical Oncology*, 32(34), p.3810.
- [25]. Schwartz, C.L., 1999. Long-term survivors of childhood cancer: the late effects of therapy. *The oncologist*, 4(1), pp.45-54.
- [26]. Kinnier-Wilson, L.M., Kneale, G.W. and Stewart, A.M., 1981. Childhood cancer and pregnancy drugs. *The Lancet*, 318(8241), pp.314-315.
- [27]. Sanders, B.M. and Draper, G.J., 1979. Childhood cancer and drugs in pregnancy. *Br Med J*, 1(6165), pp.717-718.
- [28]. Gilman, E.A., Margaret, L., Wilson, K., Kneale, G.W. and Waterhouse, J.A.H., 1989. Childhood cancers and their association with pregnancy drugs and illnesses. *Paediatric and perinatal epidemiology*, 3(1), pp.66-94.
- [29]. Sorahan, T., Lancashire, R., Prior, P., Peck, I. and Stewart, A., 1995. Childhood cancer and parental use of alcohol and tobacco. *Annals of epidemiology*, 5(5), pp.354-359.
- [30]. Sorahan, T., Lancashire, R.J., Hulten, M.A., Peck, I. and Stewart, A.M., 1997. Childhood cancer and parental use of tobacco: deaths from 1953 to 1955. *British journal of cancer*, 75(1), pp.134-138.
- [31]. Sorahan, T., Prior, P., Lancashire, R.J., Faux, S.P., Hulten, M.A., Peck, I.M. and Stewart, A.M., 1997. Childhood cancer and parental use of tobacco: deaths from 1971 to 1976. *British journal of cancer*, 76(11), pp.1525-1531.
- [32].] Draper, G.J., Bithell, J.F., Bunch, K.J., Kendall, G.M., Murphy, M.F. and Stiller, C.A., 2018. Childhood cancer research in Oxford II: the childhood cancer research group. *British journal of cancer*, 119(6), pp.763-770.
- [33]. Hewitt, D., Lashof, J.C. and Stewart, A.M., 1966. Childhood cancer in twins. *Cancer*, 19(2), pp.157-161.

- [34]. Piñeros, M., Znaor, A., Mery, L. and Bray, F., 2017. A global cancer surveillance framework within noncommunicable disease surveillance: making the case for population-based cancer registries. *Epidemiologic reviews*, 39(1), pp.161-169.
- [35]. Byrne, J., Alessi, D., Allodji, R.S., Bagnasco, F., Bárdi, E., Bautz, A., Bright, C.J., Brown, M., Diallo, I., Feijen, E.A.L. and Fidler, M.M., 2018. The PanCareSurFup consortium: research and guidelines to improve lives for survivors of childhood cancer. *European journal of cancer*, 103, pp.238-248.
- [36]. Winther, J.F., Kenborg, L., Byrne, J., Hjorth, L., Kaatsch, P., Kremer, L.C., Kuehni, C.E., Auquier, P., Michel, G., De Vathaire, F. and Haupt, R., 2015. Childhood cancer survivor cohorts in Europe. *Acta oncologica*, 54(5), pp.655-668.
- [37]. Pritchard-Jones, K., Pieters, R., Reaman, G.H., Hjorth, L., Downie, P., Calaminus, G., Naafs-Wilstra, M.C. and Steliarova-Foucher, E., 2013. Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries. *The lancet oncology*, 14(3), pp.e95-e103.
- [38]. Magrath, I., Steliarova-Foucher, E., Epelman, S., Ribeiro, R.C., Harif, M., Li, C.K., Kebudi, R., Macfarlane, S.D. and Howard, S.C., 2013. Paediatric cancer in low-income and middle-income countries. *The lancet oncology*, 14(3), pp.e104-e116.
- [39]. Wild, C.P. and Stewart, B.W. eds., 2014. *World cancer report 2014* (pp. 482-494). Geneva, Switzerland: World Health Organization
- [40]. Mosse, Y.P., Balis, F.M., Lim, M.S., Laliberte, J., Voss, S.D., Fox, E., Bagatell, R., Weigel, B., Adamson, P.C., Ingle, A.M. and Ahern, C.H., 2012. Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: A Children's Oncology Group phase I consortium study.
- [41]. Schlegel, P., Lang, P., Zugmaier, G., Ebinger, M., Kreyenberg, H., Witte, K.E., Feucht, J., Pfeiffer, M., Teltschik, H.M., Kyzirakos, C. and Feuchtinger, T., 2014. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. *haematologica*, 99(7), p.1212.
- [42]. Topp, M.S., Gökbüget, N., Stein, A.S., Zugmaier, G., O'Brien, S., Bargou, R.C., Dombret, H., Fielding, A.K., Heffner, L., Larson, R.A. and Neumann, S., 2015. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. *The Lancet Oncology*, 16(1), pp.57-66.
- [43]. Grupp, S.A., Kalos, M., Barrett, D., Aplenc, R., Porter, D.L., Rheingold, S.R., Teachey, D.T., Chew, A., Hauck, B., Wright, J.F. and Milone, M.C., 2013. Chimeric antigen receptor–modified T cells for acute lymphoid leukemia. *New England Journal of Medicine*, 368(16), pp.1509-1518.
- [44]. Porter, D.L., Levine, B.L., Kalos, M., Bagg, A. and June, C.H., 2011. Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia. *N engl j Med*, 365, pp.725-733.
- [45]. Jones, B.L., 2006. Companionship, control, and compassion: A social work perspective on the needs of children with cancer and their families at the end of life. *Journal of palliative medicine*, 9(3), pp.774-788.
- [46]. Scott, B., 2011. *The present giver: a memoir*. ALM.
- [47]. James, K., Keegan-Wells, D., Hinds, P.S., Kelly, K.P., Bond, D., Hall, B., Mahan, R., Moore, I.M., Roll, L. and Speckhart, B., 2002. The care of my child with cancer: parents' perceptions of caregiving demands. *Journal of Pediatric Oncology Nursing*, 19(6), pp.218-228.
- [48]. Gatta, G., Botta, L., Rossi, S., Aareleid, T., Bielska-Lasota, M., Clavel, J., Dimitrova, N., Jakab, Z., Kaatsch, P., Lacour, B. and Mallone, S., 2014. Childhood cancer survival in Europe 1999–2007: results of EUROCare-5—a population-based study. *The lancet oncology*, 15(1), pp.35-47.
- [49]. Smith, M.A., Seibel, N.L., Altekruse, S.F., Ries, L.A., Melbert, D.L., O'Leary, M., Smith, F.O. and Reaman, G.H., 2010. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. *Journal of clinical oncology*, 28(15), p.2625.
- [50]. Basta, N.O., James, P.W., Gomez-Pozo, B., Craft, A.W. and McNally, R.J.Q., 2011. Survival from childhood cancer in northern England, 1968–2005. *British journal of cancer*, 105(9), pp.1402-1408.
- [51]. Johnston, W.T., Lightfoot, T.J., Simpson, J. and Roman, E., 2010. Childhood cancer survival: a report from the United Kingdom Childhood Cancer Study. *Cancer Epidemiology*, 34(6), pp.659-666.
- [52]. Pritchard-Jones, K., Pieters, R., Reaman, G.H., Hjorth, L., Downie, P., Calaminus, G., Naafs-Wilstra, M.C. and Steliarova-Foucher, E., 2013. Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries. *The lancet oncology*, 14(3), pp.e95-e103.
- [53]. Steliarova-Foucher, E., Frazier, L., Stewart, B.W. and Wild, C.P., 2014. Childhood cancer. *World cancer report*, pp.69-76.
- [54]. Wiangnon, S., Kamsa-Ard, S., Jetsrisuparb, A., Sriplung, H., Sontipong, S., Sumitsawan, Y. and Martin, N., 2003. Childhood cancer in Thailand: 1995-1997. *Asian Pacific Journal of Cancer Prevention*, 4(4), pp.337-343.
- [55]. Swaminathan, R., Rama, R. and Shanta, V., 2008. Childhood cancers in Chennai, India, 1990–2001: incidence and survival. *International journal of cancer*, 122(11), pp.2607-2611.
- [56]. Bao, P.P., Zheng, Y., Wang, C.F., Gu, K., Jin, F. and Lu, W., 2009. Time trends and characteristics of childhood cancer among children age 0–14 in Shanghai. *Pediatric blood & cancer*, 53(1), pp.13-16.
- [57]. Howlader, N. and Noone, A.M., 2015. Krapcho Met al., eds. *SEER Cancer Statistics Review, 1975–2010*. Bethesda, MD: National Cancer Institute; 2013.